Sapanisertib 是一种口服有效的 ATP 依赖性的mTOR1/2抑制剂，抑制 mTOR 激酶的IC50值为 1 nM，具有潜在抗肿瘤活性。

INK 128 is an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2) with potential antineoplastic activity.

每日给多种移植体模型中口服给药INK 128,抑制血管生成和肿瘤生长.每天给ZR-75-1乳腺癌异种移植模型用0.3 mg/kg INK 128处理显示对肿瘤生长的抑制效果.

INK 128作为TORC1/2抑制剂,抑制TORC1的下游底物S6和4EBP1的磷酸化,并选择性抑制TORC2下游底物Ser473上的AKT磷酸化。INK 128对mTOR表现出酶抑制活性,对PI3K激酶的选择性高100倍以上。此外,INK 128还对雷帕霉素和pan-PI3K抑制剂耐药的细胞系显示出有效的抑制作用。

mTOR activity is assayed using LanthaScreen Kinase kit reagents. PI(3)K α, β, γ and δ activity are assayed using the PI(3)K HTRF assay kit. The concentration of INK128 necessary to achieve inhibition of enzyme activity by 50% (IC50) is calculated using concentrations ranging from 20 μM to 0.1 nM (12-point curve). IC50?values are determined using a nonlinear regression model.

PC3 cells are treated with the appropriate drug for 48 h, and proliferation is measured using CellTiter-Glo Luminescent reagent. The concentration of INK128 necessary to achieve inhibition of cell growth by 50% (IC50) is calculated using concentrations ranging from 20.0 μM to 0.1 nM (12-point curve).

1224844-38-5

C15H15N7O

309.333

MLN0128;INK 128;沙帕色替;TAK-228

H2O:<1 mgml
DMSO:58 mg/mL (187.5 mM)
Ethanol:2 mg/mL (6.46 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years